Nicolas Girard, MD

Articles

Dr Girard on Nivolumab Plus Relatlimab and Chemotherapy in Stage IV or Recurrent NSCLC

September 14th 2024

Nicolas Girard, MD, discusses the RELATIVITY-104 trial of nivolumab plus relatlimab and chemotherapy in previously untreated stage IV or recurrent NSCLC.

Dr Girard on the Development of ADCs in Patients With NSCLC

October 27th 2023

Nicholas Girard, MD, PhD, discusses the evolving role of antibody-drug conjugates in the treatment of patients with non–small cell lung cancer, highlighting data from the phase 3 TROPION-Lung01 study.

Dr Girard on the Efficacy of First-Line Amivantamab Plus Chemotherapy in EGFR Exon 20 Insertion+ NSCLC

October 21st 2023

Nicolas Girard, MD, PhD, discusses primary efficacy results from the phase 3 PAPILLON trial of amivantamab plus chemotherapy in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

Dr. Girard on Examining the Real-World Effectiveness of Lurbinectedin in SCLC

September 26th 2022

Nicolas Girard, MD, PhD, discusses the investigation of lurbinectedin in small cell lung cancer.

Dr. Girard on the Next Steps With Durvalumab in NSCLC

October 29th 2021

Nicolas Girard, MD, discusses the next steps with durvalumab in non–small cell lung cancer.

Dr. Girard on Real-World PFS Data With Durvalumab in NSCLC

October 5th 2021

Nicolas Girard, MD, discusses the progression-free survival data with durvalumab observed in a real-world analysis of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer.

Dr. Girard on Rationale for PACIFIC-R Study for NSCLC

July 13th 2019

Nicolas Girard, MD, discusses the rationale for the PACIFIC-R study, which is examining patients with unresectable stage III non–small cell lung cancer who received durvalumab.

Dr. Girard on Maximizing Outcomes of Lung Cancer Treatments

January 6th 2017

Nicolas Girard, MD, professor of Respiratory Medicine and Thoracic Oncology at the Claude Bernard University in Lyon, France, and senior attending physician in the Thoracic Oncology Service of the Hospices Civils de Lyon, discusses the optimal methods to maximize the outcomes of crizitonib (Xalkori) when used as a treatment for patients with non-small cell lung cancer (NSCLC).